Theodore Chu, MD
Allergy · San Jose, CANPI 1194765123
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 320 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by GSK at 43.1% of the total. 2025 is the largest year on record at $2,105, 3.4 times the $620 reported in 2019.
Across 320 payments — averaging $30.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- AstraZeneca$3K
- Sanofi$1K
- Boehringer Ingelheim$414
- Regeneron Healthcare Solutions, Inc.$339
- Novartis$201
- plus $1K from 16 others
What the payments were for
- Food & beverage$9,706100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 139 | $4,182 |
| AstraZeneca | 80 | $2,523 |
| Sanofi | 30 | $1,015 |
| Boehringer Ingelheim | 17 | $414 |
| Regeneron Healthcare Solutions, Inc. | 12 | $339 |
| Novartis | 7 | $201 |
| Lilly USA, LLC | 3 | $189 |
| Mylan Specialty L.p. | 5 | $144 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $109 |
| Teva Pharmaceuticals USA, Inc. | 4 | $93 |
| Amgen | 3 | $85 |
| Genentech USA, Inc. | 3 | $79 |
| Galderma Laboratories, L.p. | 2 | $61 |
| Kaleo, Inc. | 2 | $52 |
| Greer Laboratories, Inc. | 1 | $38 |
| Pfizer | 2 | $38 |
| Verona Pharma, Inc. | 1 | $31 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Philips North America LLC | 1 | $24 |
| Optinose US, Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,714 in reported general payments places this provider in the 75th percentile of 117 allergy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $35,645 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 47 | $10,460 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,567 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,513 |
| Azelastine Hcl | 69 | $1,086 |
| Montelukast Sodium | 104 | $980 |
| Ventolin HfaAlbuterol Sulfate | 14 | $775 |
| Fluticasone Propionate | 58 | $662 |
| Triamcinolone Acetonide | 73 | $448 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $154 |
| Famotidine | 22 | $130 |
| Prednisone | 30 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $4,182 | $35,64547 claims |
| Boehringer IngelheimSpiriva Respimat | $414 | $5,56711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 117 allergy providers in California.
Other allergy in San Jose
- John KelloggSan Jose$17K
- Anlin XuSan Jose$16K
- Alan HellerSan Jose$10K
- Joshua JacobsWalnut Creek$1.5M
- Warner CarrLaguna Niguel$571K
- Bradley ChippsSacramento$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
- William BergerMission Viejo$76K
- Sandra ChristiansenSan Diego$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.